144 related articles for article (PubMed ID: 19826800)
1. Drug dosage protocol for calcium oxalate stone.
Marickar YM; Salim A
Urol Res; 2009 Dec; 37(6):353-7. PubMed ID: 19826800
[TBL] [Abstract][Full Text] [Related]
2. Clinical results of allopurinol treatment in prevention of calcium oxalate stone formation.
Tiselius HG; Larsson L; Hellgren E
J Urol; 1986 Jul; 136(1):50-3. PubMed ID: 3712614
[TBL] [Abstract][Full Text] [Related]
3. [A study of allopurinol in the prevention of recurrent calcium oxalate stones].
Sonoda T; Koide T; Oka T; Sakaguchi H; Itatani H; Ohkawa T; Ebisuno S; Morimoto S; Yoshida O; Okada Y
Hinyokika Kiyo; 1985 Nov; 31(11):2071-9. PubMed ID: 4091144
[TBL] [Abstract][Full Text] [Related]
4. Impact of allopurinol treatment on the prevention of hyperuricosuric calcium oxalate lithiasis.
Hofbauer J; Zechner O
Eur Urol; 1988; 15(3-4):227-9. PubMed ID: 3215256
[TBL] [Abstract][Full Text] [Related]
5. Effect of combined supplementation of magnesium oxide and pyridoxine in calcium-oxalate stone formers.
Rattan V; Sidhu H; Vaidyanathan S; Thind SK; Nath R
Urol Res; 1994; 22(3):161-5. PubMed ID: 7992461
[TBL] [Abstract][Full Text] [Related]
6. Allopurinol for stones: right drug--wrong reasons.
Grover PK; Ryall RL
Am J Med; 2007 May; 120(5):380. PubMed ID: 17466643
[No Abstract] [Full Text] [Related]
7. Possibilities for preventing recurrent calcium stone formation: principles for the metabolic evaluation of patients with calcium stone disease.
Tiselius HG;
BJU Int; 2001 Jul; 88(2):158-68. PubMed ID: 11446874
[No Abstract] [Full Text] [Related]
8. Biochemical studies on bilharzial and nonbilharzial hyperoxaluria: effect of pyridoxine and allopurinol treatment.
el-Habet AE; el-Sewedy SM; el-Sharaky A; Gaafar NK; Abdel-Rafee A; Hamoud F
Biochem Med Metab Biol; 1987 Aug; 38(1):1-8. PubMed ID: 3663392
[TBL] [Abstract][Full Text] [Related]
9. Allopurinol and thiazide effects on new urinary stone formed after discontinued therapy in patients with urinary stones.
Kohri K; Kodama M; Katayama Y; Ishikawa Y; Takada M; Kataoka K; Katoh Y; Iguchi M; Kurita T
Urology; 1990 Oct; 36(4):309-14. PubMed ID: 2219608
[TBL] [Abstract][Full Text] [Related]
10. Effects of oral pyridoxine upon plasma and 24-hour urinary oxalate levels in normal subjects and stone formers with idiopathic hypercalciuria.
Edwards P; Nemat S; Rose GA
Urol Res; 1990; 18(6):393-6. PubMed ID: 2100414
[TBL] [Abstract][Full Text] [Related]
11. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
[TBL] [Abstract][Full Text] [Related]
12. Allopurinol for calcium oxalate stones?
Lancet; 1987 Jan; 1(8527):258-9. PubMed ID: 2880074
[No Abstract] [Full Text] [Related]
13. Do indomethacin, thiazide, pyridoxine or allopurinol prevent calcium oxalate stones?
Reis-Santos JM; Guimarães P; Correia R; Ferreira AM
Contrib Nephrol; 1987; 58():176-80. PubMed ID: 3691121
[No Abstract] [Full Text] [Related]
14. Change in inhibitory potential in urine of hyperuricosuric calcium oxalate stone formers effected by allopurinol and orthophosphates.
Goldwasser B; Sarig S; Azoury R; Wax Y; Hirsch D; Perlberg S; Many M
J Urol; 1984 Nov; 132(5):1008-11. PubMed ID: 6492268
[TBL] [Abstract][Full Text] [Related]
15. Formation of calcium oxalate urolithiasis in experiment and its inhibition by pyridoxine and magnesium.
Krídl J; Zvara V; Revúsová V; Ondrus B
Czech Med; 1986; 9(3):124-9. PubMed ID: 3095070
[TBL] [Abstract][Full Text] [Related]
16. Selected medical aspects of the problem of calcium oxalate stones: a review.
Rose GA
J R Soc Med; 1982 Nov; 75(11):897-9. PubMed ID: 6754926
[No Abstract] [Full Text] [Related]
17. Allopurinol for the prevention of calcium oxalate calculi.
Ulmann A
N Engl J Med; 1987 May; 316(22):1415-6. PubMed ID: 3574420
[No Abstract] [Full Text] [Related]
18. Effect of pyridoxine supplementation on recurrent stone formers.
Murthy MS; Farooqui S; Talwar HS; Thind SK; Nath R; Rajendran L; Bapna BC
Int J Clin Pharmacol Ther Toxicol; 1982 Sep; 20(9):434-7. PubMed ID: 7141762
[TBL] [Abstract][Full Text] [Related]
19. Allopurinol in the recurrence prevention of calcium oxalate lithiasis.
Brien G; Bick C
Eur Urol; 1977; 3(1):35-6. PubMed ID: 837952
[TBL] [Abstract][Full Text] [Related]
20. Prevention of stone disease.
Porena M; Guiggi P; Micheli C
Urol Int; 2007; 79 Suppl 1():37-46. PubMed ID: 17726351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
